Exelixis
EXEL
#1321
Rank
A$24.60 B
Marketcap
A$100.86
Share price
1.25%
Change (1 day)
58.26%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): A$0.43

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$5.02. In 2022 the company made an earnings per share (EPS) of A$0.83 a decrease over its 2021 EPS that were of A$1.07.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)A$0.43-48.3%
2022A$0.83-22.97%
2021A$1.07100%
2020A$0.54-65.09%
2019A$1.54-53.91%
2018A$3.33333.96%
2017A$0.77-260.61%
2016A-$0.48-58.75%
2015A-$1.16-42.45%
2014A-$2.025.3%
2013A-$1.9143.48%
2012A-$1.33-264.29%
2011A$0.81-165.88%
2010A-$1.23-32.54%
2009A-$1.83-17.65%
2008A-$2.2275.86%
2007A-$1.26-25.64%
2006A-$1.708.33%
2005A-$1.57-42.86%
2004A-$2.7430.34%
2003A-$2.10-5.23%
2002A-$2.22-0.65%
2001A-$2.23-51.87%
2000A-$4.64

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
A$9.69 93.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$1.10-78.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$23.51 368.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$2.76-45.00%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$1.44-71.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$6.55 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$4.17-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
A-$20.61-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.22-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA